Current and future intratumoral targeted treatment for pancreatic cancer.
Τίτλος | Current and future intratumoral targeted treatment for pancreatic cancer. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Zarogoulidis, P., Pavlioglou P., Le Pivert P., Machairiotis N., Katsikogiannis N., Kougioumtzi I., Tsimogiannis K., Kakolyris S., Courcoutsakis N., Tsiouda T., Sakkas A., Makrantonaki D., & Zarogoulidis K. |
Journal | Ther Deliv |
Volume | 5 |
Issue | 8 |
Pagination | 913-26 |
Date Published | 2014 Aug |
ISSN | 2041-5990 |
Λέξεις κλειδιά | Genes, p16, Humans, Molecular Targeted Therapy, NF-kappa B, Pancreatic Neoplasms, Protein-Serine-Threonine Kinases, Proto-Oncogene Proteins, ras Proteins, Vascular Endothelial Growth Factor A |
Abstract | Pancreatic cancer is an insidious type of cancer with its symptoms manifested upon extensive disease. The overall 5-year survival rates between 0.4 and 4%. Surgical resection is an option for only 10% of the patients with pancreatic cancer. Local recurrence and hepatic metastases occur within 2 years after surgery. There are currently several molecular pathways investigated and novel targeted treatments are on the market. However; the nature of pancreatic cancer with its ability to spread locally in the primary site and lymph nodes indicates that further experimentation with local interventional therapies could be a future treatment proposal as palliative care or adjunct to gene therapy and chemotherapy/radiotherapy. In the current review, we will summarize the molecular pathways and present the interventional treatment options for pancreatic cancer. |
DOI | 10.4155/tde.14.44 |
Alternate Journal | Ther Deliv |
PubMed ID | 25337648 |